Factors Associated With Long-term Retention in Antiretroviral Therapy Among People Living With HIV: Evidence From a Tertiary Hospital in Jakarta, Indonesia.

IF 2.8 Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Ifael Yerosias Mauleti, Krishna Adi Wibisana, Djati Prasetio Syamsuridzal, Sri Mulyati, Vivi Lisdawati, Ika Saptarini, Nurhayati, Armedy Ronny Hasugian, Harimat Hendarwan
{"title":"Factors Associated With Long-term Retention in Antiretroviral Therapy Among People Living With HIV: Evidence From a Tertiary Hospital in Jakarta, Indonesia.","authors":"Ifael Yerosias Mauleti, Krishna Adi Wibisana, Djati Prasetio Syamsuridzal, Sri Mulyati, Vivi Lisdawati, Ika Saptarini, Nurhayati, Armedy Ronny Hasugian, Harimat Hendarwan","doi":"10.3961/jpmph.23.512","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>This study investigated factors associated with the retention of people living with human immunodeficiency virus (HIV) on antiretroviral therapy (ART) during the first 3 years of treatment.</p><p><strong>Methods: </strong>A retrospective study using electronic health records was conducted at a tertiary hospital in Jakarta, Indonesia. Adult HIV-positive patients who started ART from 2010 until 2020 were included. A binary logistic regression model was used to identify factors associated with ART retention in the first 3 years.</p><p><strong>Results: </strong>In total, 535 respondents were included in the analysis. The ART retention rates for the first, second, and third years were 83.7%, 79.1%, and 77.2%, respectively. The multivariate analysis revealed a negative association between CD4 count when starting ART and retention. Patients with CD4 counts >200 cells/mL were 0.65 times less likely to have good retention than those with CD4 counts ≤200 cells/mL. The year of starting ART was also significantly associated with retention. Patients who started ART in 2010-2013 or 2014-2016 were less likely to have good retention than those who started ART in 2017-2020, with adjusted odds ratios of 0.52 and 0.40, respectively. Patients who received efavirenz-based therapy were 1.69 times more likely to have good retention than those who received nevirapine (95% confidence interval, 1.05 to 2.72).</p><p><strong>Conclusions: </strong>Our study revealed a decline in ART retention in the third year. The CD4 count, year of enrollment, and an efavirenz-based regimen were significantly associated with retention. Patient engagement has long been a priority in HIV programs, with interventions being implemented to address this issue.</p>","PeriodicalId":16893,"journal":{"name":"Journal of Preventive Medicine and Public Health","volume":" ","pages":"252-259"},"PeriodicalIF":2.8000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11164604/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Preventive Medicine and Public Health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3961/jpmph.23.512","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/4/30 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: This study investigated factors associated with the retention of people living with human immunodeficiency virus (HIV) on antiretroviral therapy (ART) during the first 3 years of treatment.

Methods: A retrospective study using electronic health records was conducted at a tertiary hospital in Jakarta, Indonesia. Adult HIV-positive patients who started ART from 2010 until 2020 were included. A binary logistic regression model was used to identify factors associated with ART retention in the first 3 years.

Results: In total, 535 respondents were included in the analysis. The ART retention rates for the first, second, and third years were 83.7%, 79.1%, and 77.2%, respectively. The multivariate analysis revealed a negative association between CD4 count when starting ART and retention. Patients with CD4 counts >200 cells/mL were 0.65 times less likely to have good retention than those with CD4 counts ≤200 cells/mL. The year of starting ART was also significantly associated with retention. Patients who started ART in 2010-2013 or 2014-2016 were less likely to have good retention than those who started ART in 2017-2020, with adjusted odds ratios of 0.52 and 0.40, respectively. Patients who received efavirenz-based therapy were 1.69 times more likely to have good retention than those who received nevirapine (95% confidence interval, 1.05 to 2.72).

Conclusions: Our study revealed a decline in ART retention in the third year. The CD4 count, year of enrollment, and an efavirenz-based regimen were significantly associated with retention. Patient engagement has long been a priority in HIV programs, with interventions being implemented to address this issue.

艾滋病病毒感染者长期接受抗逆转录病毒疗法的相关因素:来自印度尼西亚雅加达一家三甲医院的证据。
研究目的本研究调查了艾滋病病毒感染者在接受抗逆转录病毒疗法(ART)治疗的头 3 年中保持治疗的相关因素:印度尼西亚雅加达的一家三甲医院利用电子健康记录开展了一项回顾性研究。研究纳入了从 2010 年至 2020 年开始接受抗逆转录病毒疗法的成年 HIV 阳性患者。研究采用二元逻辑回归模型来确定与抗逆转录病毒疗法前 3 年保留率相关的因素:共有 535 名受访者参与了分析。第一年、第二年和第三年的抗逆转录病毒疗法保留率分别为 83.7%、79.1% 和 77.2%。多变量分析显示,开始接受抗逆转录病毒疗法时的 CD4 细胞数与保留率呈负相关。CD4 细胞计数大于 200 cells/mL 的患者保持良好疗效的几率是 CD4 细胞计数小于 200 cells/mL 的患者的 0.65 倍。开始抗逆转录病毒疗法的年份也与保持率有显著关系。2010-2013年或2014-2016年开始接受抗逆转录病毒疗法的患者比2017-2020年开始接受抗逆转录病毒疗法的患者更不可能保持良好的疗效,调整后的几率比分别为0.52和0.40。与接受奈韦拉平治疗的患者相比,接受依非韦伦治疗的患者保持良好疗效的可能性高出1.69倍(95% CI,1.05-2.72):我们的研究显示,抗逆转录病毒疗法的保留率在第三年有所下降。结论:我们的研究显示,抗逆转录病毒疗法的保留率在第三年有所下降,CD4计数、入组年份和基于依非韦伦的治疗方案与保留率显著相关。长期以来,患者参与一直是艾滋病项目的优先事项,目前正在实施干预措施来解决这一问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Preventive Medicine and Public Health
Journal of Preventive Medicine and Public Health Medicine-Public Health, Environmental and Occupational Health
CiteScore
6.40
自引率
0.00%
发文量
60
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信